PA 99/12
A new NHS community pharmacy scheme to help patients understand and get the best out of a new medicine is to be tested and evaluated by a team led by The University of Nottingham in collaboration with
University College London and
Warwick Business School.
The New Medicine Service started in October 2011 and will run until March 2013 with funding of up to £55 million in both 2011/12 and 2012/13 available for its delivery. The service provides support from community pharmacists for people with long-term conditions who are newly prescribed a medicine to help them solve any problems with their medication or its management.
The study is being led by
Professor Rachel Elliott and
Dr Matthew Boyd. Dr Boyd said: “The New Medicine Service is a great opportunity to formalise the excellent work community pharmacists already do every day supporting patients with their medicines. This study intends to provide an evidence base for how pharmacists can support patients with their new medicines. It is hoped it will inform the development of more pharmacy services in the future.”
Professor Nick Barber from the UCL School of Pharmacy and a project team member, whose work formed the basis for this new service said: “We hope this service will make patients’ lives better; our task is to find out if this happens in reality.”
It is believed that up to a quarter of people with long-term conditions such as asthma and diabetes don’t take their medicines properly. Under the New Medicine Service, community pharmacists offer follow-up consultations and phone calls to patients to help them manage their medicines regime. These take place one to two weeks after receiving the new medicine and again a further two to three weeks later.
The aim is to help more patients take their newly prescribed medicines correctly to improve the drugs’ effectiveness and improve outcomes for patients. It is also hoped this will reduce medicines wastage and hospital admissions due to adverse reactions to medicines.
Following an open competitive tender, a team led by investigators from The University of Nottingham’s School of Pharmacy has been awarded a £442,000 grant from the Department of Health to carry out a randomised control study of the new scheme in the East Midlands, South Yorkshire and London areas and will compare the experiences of patients who receive the New Medicine Service with those who do not. In addition researchers will interview patients, pharmacists and GPs to get grass roots experiences of how the service improves outcomes for patients and opinions on how the service could be improved. The study will run for 18 months from January 2012 reporting to the Department of Health in summer 2013.
The results of the research will inform decisions at government-level about whether the New Medicine Service should continue to be funded and future arrangements for service provision.
More details can be found on the NHS Employers website.
—Ends—
For up to the minute media alerts, follow us on Twitter
Notes to editors: The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has 40,000 students at award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK's Top 10 and the World's Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘the world’s greenest university’ in the UI GreenMetric World University Ranking 2011.
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise. The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health. The University won a Queen’s Anniversary Prize for Higher and Further Education in 2011, for its research into global food security.
Impact: The Nottingham Campaign, its biggest ever fund-raising campaign, will deliver the University’s vision to change lives, tackle global issues and shape the future. More news